Identifying EGFR as a potential CD166 interaction protein, and a subsequent endogenous co-IP assay confirmed this interaction.
Finding that CD166 significantly enhanced EGFR phosphorylation and prolonged EGF/EGFR signalling pathway activation.
Pinpointing the CD166 as an intriguing therapeutic target for patients suffered from oral squamous cell carcinoma.